Retevmo
Selpercatinib
Why Retevmo Costs $14,375.00 Per Claim
Retevmo (Selpercatinib) is used to treat cancer. According to CMS Medicare Part D spending data, the program spent $345.0M on this drug, covering 2,800 beneficiaries across 24,000 claims.
A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Selpercatinib or talk to their doctor about therapeutic alternatives that may cost less.
Spending on Retevmo increased by +56.3% year-over-year, driven by rapidly growing utilization and potential price increases.
Price Breakdown
Drug Details
Frequently Asked Questions
Retevmo (Selpercatinib) costs an average of $14,375.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $123,214.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Yes, a generic version of Retevmo (Selpercatinib) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Selpercatinib.
Medicare Part D spent $345.0M on Retevmo, covering 2,800 beneficiaries across 24,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Ask your pharmacist about generic Selpercatinib, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs, or ask your doctor about therapeutic alternatives in the same drug class.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.